News

AGC Biologics Expands Partnership with Rocket Pharmaceuticals

News

(SEATTLE), April 20, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has expanded its partnership with Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders.

AGC Biologics Appoints Jun Takami to General Manager/Site Head of Their Chiba, Japan Site

News

(CHIBA), April 8, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced the appointment of Jun Takami as the General Manager/Site Head, to lead the continued successful operations as well as continuous improvements at its Chiba, Japan site.

AGC Biologics to Present Their End-to-End Cell and Gene Therapy Offering at ARM’s Meeting on the Mediterranean Conference

News

(SEATTLE) April 5, 2021 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it will be attending Alliance for Regenerative Medicine’s virtual Meeting on the Mediterranean conference this week, from April 6 – 9, 2021 as a first-time attendee and Gold- and Agenda-level sponsor.

AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy

News

(SEATTLE), March 02, 2021 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector suspension capabilities.

AGC Biologics Appoints David Stewart as the New General Manager/Site Head of the Boulder, Colorado Site

News

(BOULDER), January 21, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new appointment to oversee the startup, strategic development and operational excellence in large-scale biologics production at its Boulder, Colorado site. Effective February 1, 2021, David Stewart will join the Boulder team as the General Manager/Site Head.

AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics’ Newly Approved Libmeldy™

News

(SEATTLE), January 4, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is the first manufacturer of Orchard Therapeutics’ Libmeldy™, which was recently approved by the European Commission (EC) as a one-time therapy for eligible patients with early-onset Metachromatic Leukodystrophy (MLD).

Pierre Fabre Selects AGC Biologics as CDMO to Manufacture the Orphan Drug ER-004

News

(SEATTLE), December 21, 2020 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and debilitating genetic disorder. AGC Biologics will manufacture GMP material for the next stage of clinical trial.

AGC Biologics to Expand Biopharmaceutical CDMO Capacity

News

Doubling the production capacity at its site in Denmark to address strong demand

 

(SEATTLE), November 30, 2020 -- AGC Biologics announced that it will increase the production capacity of its Copenhagen facility. AGC Biologics will construct a new building on land adjacent to its current Copenhagen site, adding production floors with 2000L single-use bioreactors, labs and office space. The total investment for this expansion is estimated to be approximately €160M, and the start of operation is scheduled for 2023.

AGC Biologics and Horizon Therapeutics plc Expand Partnership

News

Horizon’s TEPEZZA® (teprotumumab-trbw) treatment will be produced from AGC Biologics’ new facility in Boulder, CO

 

(SEATTLE), October 29, 2020 -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced that its partnership with Horizon Therapeutics plc (Nasdaq: HZNP) is expanding to produce Horizon’s Thyroid Eye Disease (TED) treatment, TEPEZZA, at AGC’s new facility in Boulder, CO. The state-of-the-art facility includes two 20,000L stainless steel mammalian bioreactors which AGC is offering to customers who need very high-volume commercial production.

MolMed S.p.A Becomes AGC Biologics S.p.A Following the July Acquisition

News

AGC Biologics Now Provides End-to-End Cell and Gene Therapy CDMO Services


(SEATTLE), October 27, 2020 -- After its parent company AGC Inc. acquired 100% of the shares of MolMed S.p.A. on September 30, 2020, AGC Biologics announced that MolMed’s entity name has been changed to AGC Biologics S.p.A. This Center of Excellence for AGC Biologics’ cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services is in Milan, Italy. The Milan site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has unique commercial manufacturing experience, with two cell & gene therapy products. AGC Biologics is now one of the very few CDMO’s in the world offering both plasmid production and end-to-end cell and gene therapy services.

Follow Us
Join us on LinkedIn Follow us on Twitter